Jason Glanz to Opioid-Related Disorders
This is a "connection" page, showing publications Jason Glanz has written about Opioid-Related Disorders.
Connection Strength
3.277
-
Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder. JAMA Psychiatry. 2026 May 01; 83(5):491-498.
Score: 0.773
-
Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy. Subst Abus. 2023 07; 44(3):209-219.
Score: 0.644
-
Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. JAMA Netw Open. 2022 10 03; 5(10):e2234671.
Score: 0.603
-
Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS. Pain Med. 2020 10 01; 21(10):2244-2252.
Score: 0.525
-
Pharmaceutical Opioids in the Home and Youth: Implications for Adult Medical Practice. Subst Abus. 2015; 36(2):141-3.
Score: 0.355
-
Impact of increased criminal penalties for fentanyl possession on initiation and retention on medications for opioid use disorder in Colorado. Int J Drug Policy. 2025 12; 146:105037.
Score: 0.186
-
Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf. 2018 10; 41(10):979-980.
Score: 0.114
-
National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013 Aug 01; 131(3):263-70.
Score: 0.077